Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

The LuxLife full range of vision IOL is available in a range of cylinders spanning from +0.75D to +6.00D.

Insurance coverage from the second largest health plan in the US paves the way for expanded access to Luminopia’s unique amblyopia therapeutic.

When her friend began experiencing dry eye symptoms while undergoing chemotherapy, Katherine Mastrota, OD, MS, FAAO, Dipl ABO, found herself in a unique position to provide specialized advice.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in health care, alongside Cascader Limited, which was created in partnership with Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology (IoO).

Shamie encourages taking a contemporary, elevated approach to refractive surgery.

The recombinant human VEGFR antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

Selina McGee, OD, FAAO, emphasized that today’s approach to presbyopia correction must move beyond traditional methods like spectacles and contact lenses.

Investigators reported that the benefits of the training for patients with hemianopia, driven by improved blind-side scanning, lasted for more than a month.

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

Reed will be honored with the Doctor of Ocular Science honorary degree in part of the college’s 2025 commencement.

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

The law is the product of a 2-year collaborative effort by the North Dakota Optometric Association and the North Dakota State Board of Optometry.